Evotec (EVO) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oculis (OCS) has outperformed Evotec (EVO) over the past year, losing 55.4% versus a loss of 58.9%. Over five years, OCS leads with a -13.4% price change compared with -92.9% for EVO. Evotec is the larger company by market cap ($552.6 million vs $537.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | OCS |
|---|---|---|
| Share price | $1.56 | $8.73 |
| Market cap | $552.63M | $537.66M |
| 1-day change | -3.42% | +2.71% |
| YTD return | -47.73% | -57.44% |
| 1-year return | -58.93% | -55.40% |
| 5-year return | -92.87% | -13.44% |
| EPS (TTM) | $-0.64 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.27 | $34.48 |
| 52-week low | $1.50 | $8.30 |
| Distance from 52-week high | -63.58% | -74.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +167.52% | +317.98% |
| Average volume | 103.98K | 258.13K |
| Shares outstanding | 355.39M | 61.59M |
| Employees | 4,461 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
EVO vs OCS FAQ
Which is bigger, Evotec or Oculis?
Evotec (EVO) is larger, with a market capitalization of $552.63M compared with $537.66M for Oculis (OCS).
Which stock has performed better over the past year, EVO or OCS?
OCS returned -55.40% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.